Large gap with delayed quotes
|
Last quote
12/27/2024 -
16:30:00
|
Bid
12/27/2024 -
15:59:59
|
Bid Volume |
Ask
12/27/2024 -
15:59:59
|
Ask Volume |
|---|---|---|---|---|
|
313.11
-0.93
(
-0.30% )
|
313.11
|
700 |
314.48
|
400 |
Analysis date: 24.12.2024
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 13.12.2024.
Interest
Weak
Weak
Weak interest since 03.12.2024.
Earnings Rev Trend
0.10
0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is positive since 01.11.2024 at a price of 319.58.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
Positive
Positive
The forty day Medium Term Technical Trend is positive since 01.11.2024. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 289.463.
4wk Rel Perf
-10.49%
-10.49%
The four week relative underperformance versus SP500 is 10.49%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 25.06.2024.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.07%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.17%.
Mkt Cap in $bn
6.78
6.78
With a market capitalization between $2 & $8bn, MADRIGAL PHARMACEUTICALS is considered a mid-cap stock.
G/PE Ratio
0.77
0.77
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
154.19
154.19
The estimated PE is for the year 2026.
LT Growth
118.08%
118.08%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
14
14
Over the last seven weeks, an average of 14 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
6
6
For 1% of index variation, the stock varies on average by 0.06%.
Correlation
0
0
Stock movements are totally independent of index variations.
Value at Risk
74.88
74.88
The value at risk is estimated at USD 74.88. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
27.07.2018
27.07.2018